Forbion appointed John McDonald as an operating partner focused on business development and M&A, bringing experience across biopharma and earlier corporate strategy roles. The hire follows McDonald’s prior positions at Novo Nordisk, Biogen, and MPM Capital, expanding Forbion’s senior bench for partnering and portfolio expansion. The move is consistent with Forbion’s model of active investment support as biotech deals remain active and many mid-stage assets look for strategic paths. In parallel, the firm is also promoting internal capability and partner coverage to accelerate sourcing and execution. McDonald’s appointment underscores the continuing importance of deal-making expertise in venture and late-stage investing environments, particularly for platforms seeking cross-border commercial development.